CDK 4/6 inhibitors combined with radiotherapy: A review of literature

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) namely palbociclib, ribociclib and abemaciclib were granted approval by the European Medicines Agency (EMA) between 2017 and 2018. They are currently prescribed in combination with hormone therapy to treat hormone receptor positive, HER2 negative...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosacki, Claire, Bouleftour, Wafa, Sotton, Sandrine, Vallard, Alexis, Daguenet, Elisabeth, Ouaz, Hamza, Cojoracu, Iohel, Moslemi, Dariush, Molekzadehmoghani, Mona, Magné, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724290/
https://www.ncbi.nlm.nih.gov/pubmed/33319074
http://dx.doi.org/10.1016/j.ctro.2020.11.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724290/
https://www.ncbi.nlm.nih.gov/pubmed/33319074
http://dx.doi.org/10.1016/j.ctro.2020.11.010

Ejemplares similares